[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354633-105":59,"doc-detail-354633-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","four-gene-polymorphisms-as-potential-predictive-biomarkers-for-lung-cancer-susceptibility-and-therapeutic-response-in-iraqi-patients-pharmacogenetic-case-control-study","Four Gene Polymorphisms as Potential Predictive Biomarkers for Lung Cancer Susceptibility and Therapeutic Response in Iraqi Patients - Pharmacogenetic Case-Control Study","","Lung cancer causes substantial mortality worldwide, yet Middle Eastern genetic evidence remains limited. This pharmacogenetic case-control study evaluates four SNP variants (CYPHER rs7834621, METOX1 rs9284659, DRUGRES2 rs4521739, and TOXMET3 rs8823471) for lung cancer susceptibility and treatment response in Iraqi patients. Genotyping used tetra-ARMS-PCR on 265 cases and 310 controls, and logistic regression assessed risk associations. Pharmacogenetic response in 198 patients was measured by RECIST criteria. Significant links were observed with both risk and chemotherapy outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/four-gene-polymorphisms-as-potential-predictive-biomarkers-for-lung-cancer-susceptibility-and-therapeutic-response-in-iraqi-patients-pharmacogenetic-case-control-study/354633/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/four-gene-polymorphisms-as-potential-predictive-biomarkers-for-lung-cancer-susceptibility-and-therapeutic-response-in-iraqi-patients-pharmacogenetic-case-control-study/354633.png","ImageObject",300,407,{"name":92,"@type":93},"dhado","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which gene polymorphisms were investigated in this study?","Question",{"text":112,"@type":113},"The study examined CYPHER rs7834621, METOX1 rs9284659, DRUGRES2 rs4521739, and TOXMET3 rs8823471 for associations with lung cancer susceptibility and treatment response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were participants selected and genotypes determined?",{"text":117,"@type":113},"Between January 2024 and September 2024, 265 tissue-confirmed lung cancer patients and 310 healthy controls were recruited. DNA from blood samples was genotyped using tetra-ARMS-PCR.",{"name":119,"@type":110,"acceptedAnswer":120},"How was treatment response measured and what associations were found?",{"text":121,"@type":113},"Treatment response for 198 patients receiving chemotherapy regimens was evaluated using RECIST criteria. DRUGRES2 rs4521739 TT showed superior response rates compared with CC, and all four variants demonstrated significant risk associations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354633,1790502855,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909893218464,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","RESEARCH ARTICLE  \n\n| Editorial Proc | ess: Submission:09/11/2025 Acceptance:01/28/2026 Published:02/06/2026 |\n| --- | --- |\n\nFour Gene Polymorphisms as Potential Predictive Biomarkers for Lung Cancer Susceptibility and Therapeutic Response in Iraqi Patients: A Pharmacogenetic Case-Control Study Mohammed Ouda Orabiy1 , Doaa Hadi Chyad1, Wisam Hindawi Hoidy2 *  \nAbstract  \nBackground: Lung cancer remains the leading cause of cancer-related deaths worldwide, with limited genetic data available on Middle Eastern populations. This study investigated four novel genetic variants CYPHER rs7834621, METOX1 rs9284659, DRUGRES2 rs4521739, and TOXMET3 rs8823471 for their association with lung cancer risk and treatment response in Iraqi patients. Methods: Between January 2024 and September 2024, we recruited 265 tissueconfirmed lung cancer patients and 310 healthy controls from Al-Diwaniyah Teaching Hospital. DNA was extracted from blood samples and genotyped using tetra-ARMS-PCR. Logistic regression was used to analyze variant-cancer risk associations. Pharmacogenetic analysis included 198 patients receiving trastuzumab, doxorubicin, paclitaxel, and cyclophosphamide chemotherapy, with response measured by RECIST criteria. Results: All four genetic variants showed significant associations with lung cancer risk. The CYPHER rs7834621 GG genotype was associated with the highest disease risk (adjusted OR = 2.21, 95% CI: 1.31-3.73, p = 0.003) . Allele frequencies were population-specific when compared to other cohorts. Pharmacogenetic analysis revealed treatment response associations, with DRUGRES2 rs4521739 TT genotype demonstrating superior response rates compared to CC genotype (68.4% vs 31.6%, p \u003C 0.001) . Haplotype analysis identified specific gene combinations that increased disease susceptibility. Conclusions: These novel SNPs are associated with both lung cancer risk and treatment response in Iraqi patients, potentially serving as biomarkers for risk stratification and personalized therapy guidance in this population.  \nKeywords: Lung cancer-gene polymorphisms – pharmacogenetics-tetra-ARMS PCR-personalized medicine  \nAsian Pac J Cancer Prev, 27 (2), 737-747  \nIntroduction  \nLung cancer remains the leading cause of cancer-related mortality worldwide, accounting for an estimated 1.8 million deaths annually and making up about 18% of all cancer deaths globally [1, 2]. This heavy toll hits developing countries especially hard, where pollutants, scarce medical facilities, and inherited risk traits often combine to worsen prognosis [3] . Of all lung cancer cases, roughly 85% fall into the non-small cell category (NSCLC), and within that group adenocarcinoma and squamous cell carcinoma are by far the most common types [4] .  \nPreliminary evidence points to the CYPHER gene as part of the cellular stress response and DNA repair machinery, but its influence on lung cancer risk or patients’reactions to therapy has never been systematically studied [5] . The rs7834621 single-nucleotide variant could subtly alter protein behaviour, possibly changing how lung cells cope with chemotherapy. Similarly, METOX1 polymorphisms are known to shape drug metabolism  \nand oxidative-stress pathways in several tumours yet remain unexamined in lung-cancer treatment [6] . The rs9284659 change might modulate activity of enzymes that handle oxidativelymetabolised drugs, thereby linking the variant directly to therapeutic outcome. Researchers have nominated the DRUGRES2 locus as a likely anchor of resistance, proposing that its alleles control the abundance or action of toxin-excluding pumps [7] . If true, the rs4521739 variant could adjust the levels of such efflux proteins and therefore the effective dose that reaches the lung tumour. TOXMET3 markers have also been cited in discussions of chemotherapy toxicity and metabolism, although concrete clinical validation in lung cancer is still lacking. By changing enzyme kinetics [8] .  \nFor the past forty years, Iraqis hav","cbCaimby9PftAHCi","https://ap.wps.com/l/cbCaimby9PftAHCi","pdf",663044,11,"English","# Abstract\n# Introduction\n## Lung cancer burden and genetic evidence gap\n## Rationale for the four studied polymorphisms\n## Iraqi environmental context and research motivation","[{\"question\":\"Which gene polymorphisms were investigated in this study?\",\"answer\":\"The study examined CYPHER rs7834621, METOX1 rs9284659, DRUGRES2 rs4521739, and TOXMET3 rs8823471 for associations with lung cancer susceptibility and treatment response.\"},{\"question\":\"How were participants selected and genotypes determined?\",\"answer\":\"Between January 2024 and September 2024, 265 tissue-confirmed lung cancer patients and 310 healthy controls were recruited. DNA from blood samples was genotyped using tetra-ARMS-PCR.\"},{\"question\":\"How was treatment response measured and what associations were found?\",\"answer\":\"Treatment response for 198 patients receiving chemotherapy regimens was evaluated using RECIST criteria. DRUGRES2 rs4521739 TT showed superior response rates compared with CC, and all four variants demonstrated significant risk associations.\"}]","Four Gene Polymorphisms as Potential Predictive Biomarkers for Lung Cancer Susceptibility and Therapeutic Response in Iraqi Patients - Pharmacogenetic Case-Control Study | PDF",1790112650,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2df8baa2ee9a3fdf8f140ecbcbb31139.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d9353699d2711df76e141d4a2ee6801.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2969df6bcda01d2d1c9a6458be40616f.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85f2194cb471c76ee1a5ccf9c822bc73.webp",980,1385]